Compare SID & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | OGN |
|---|---|---|
| Founded | 1941 | 1923 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | SID | OGN |
|---|---|---|
| Price | $1.67 | $7.52 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $1.40 | ★ $11.63 |
| AVG Volume (30 Days) | 5.5M | ★ 6.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.10% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.93 | N/A |
| Revenue Next Year | N/A | $1.65 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $6.18 |
| 52 Week High | $2.20 | $16.18 |
| Indicator | SID | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 41.56 |
| Support Level | $1.63 | $6.50 |
| Resistance Level | $1.93 | $7.58 |
| Average True Range (ATR) | 0.09 | 0.42 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 5.66 | 40.93 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.